Open | - |
Close | - |
Volume / Avg. | 0 / 5.460M |
Day Range | - - - |
52 Wk Range | 0.274 - 2.990 |
Market Cap | $10.655M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 48 |
Short Interest | 0.98% |
Days to Cover | 1.94 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Monopar Therapeutics (NASDAQ: MNPR) through any online brokerage.
Other companies in Monopar Therapeutics’s space includes: Imunon (NASDAQ:IMNN), Coeptis Therapeutics (NASDAQ:COEP), BioRestorative Therapies (NASDAQ:BRTX), NexImmune (NASDAQ:NEXI) and ABVC BioPharma (NASDAQ:ABVC).
The latest price target for Monopar Therapeutics (NASDAQ: MNPR) was reported by HC Wainwright & Co. on Thursday, June 1, 2023. The analyst firm set a price target for 17.00 expecting MNPR to rise to within 12 months (a possible 2271.98% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Monopar Therapeutics (NASDAQ: MNPR) is $0.7167 last updated March 18, 2024 at 9:22 AM EDT.
There are no upcoming dividends for Monopar Therapeutics.
Monopar Therapeutics’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Monopar Therapeutics.
Monopar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.